Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference call scheduled for 9am ET REHOVOT, Israel , Nov. 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial results for the third quarter of 2022 on Thursday, November 17, 2022.

Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022

LAV.311  is targeting fruit rots and powdery mildews fungal diseases REHOVOT, Israel , Oct. 12, 2022 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Advances its Novel Bio-fungicide Program and Applies to the U.S. EPA for Regulatory Approval

REHOVOT, Israel , Oct. 6, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Ofer Haviv, Evogene's President and CEO, will attend and present at LD Micro Main Event, an investor conference taking place from Tuesday, October 25 to Wednesday, October 26, 2022, in Los Angeles.

Evogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles

The new and improved products are derived from novel proprietary cannabis varieties developed using genetic markers utilizing Evogene's GeneRator AI tech-engine REHOVOT, Israel , Sept. 21, 2022 /PRNewswire/ -- Canonic Ltd.

Canonic Launches its Second-Generation Medical Cannabis Products with High THC and Unique Terpene Profiles

REHOVOT, Israel , Sept. 14, 2022 /PRNewswire/ -- Lavie Bio Ltd.

Lavie Bio Announces Appointment of Guri Oron as CEO

Portugal-based GroVida licenses two of Canonic's cannabis varieties for cultivation and commercialization in Europe REHOVOT, Israel , Sept. 13, 2022 /PRNewswire/ -- Canonic Ltd.

Canonic Advances its Penetration into Europe by Signing its First Licensing Agreement with GroVida

REHOVOT, Israel , Sept. 7, 2022 /PRNewswire/ -- Evogene Ltd.

Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference

EverGen Infrastructure is a leading RNG producer in Canada, supplying sustainable green gas that originates from organic waste. The company has significant potential upside instilled in its pipeline projects, with about $30 million EBITDA potential by 2024, based on execution.

EverGen Infrastructure: A Micro-Cap Renewable Energy Play

HEXO Corp

Innovative Industrial Properties

SNDL Inc.

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

5 Weed Stocks That Smoked Headlines This Week

Evogene Ltd. (NASDAQ:EVGN ) Q2 2022 Earnings Conference Call August 31, 2022 9:00 AM ET Company Participants Ofer Haviv - President & CEO Russ Putland - EVP Commercial & General Manager, Lavie-Bio, Inc. Yaron Eldad - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Brian Wright - ROTH Capital Partners Brett Reiss - Janney Montgomery Scott Operator Ladies and gentlemen, thank you for standing by.

Evogene Ltd. (EVGN) Q2 2022 Earnings Call Transcript

Evogene (EVGN) delivered earnings and revenue surprises of -16.67% and 83.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q2 Loss, Tops Revenue Estimates

Conference call and webcast: today, August 31, 2022, 9:00 am ET REHOVOT, Israel , Aug. 31, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the second quarter ended June 30, 2022.

Evogene Reports Second Quarter 2022 Financial Results

ICL-Israel Chemicals

TEL AVIV, Israel--(BUSINESS WIRE)--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today a multi-year, strategic, collaboration agreement between ICL and Lavie Bio Ltd., a subsidiary of Evogene. Lavie Bio is a leading ag-biologicals company focusing on improving food quali

ADDING MULTIMEDIA ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

REHOVOT, Israel , Aug. 2, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that it will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022.

Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2022

This addition to Biomica's scientific expertise will support the company's upcoming steps in its immuno-oncology clinical development program REHOVOT, Israel , July 28, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica Appoints Professor Gal Markel to Company's Scientific Advisory Board

REHOVOT, Israel , July 26, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

REHOVOT, Israel , July 5, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at the Microbiome Connect Europe 2022

Dr. Elran Haber to participate in the Industry Leaders opening panel  at this premier Microbiome conference REHOVOT, Israel , June 15, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at the 7th Microbiome Movement Drug Development Summit

Evogene Ltd. (NASDAQ:EVGN ) Q1 2022 Results Conference Call May 26, 2022 9:00 AM ET Company Participants Ofer Haviv - CEO, President & Chairman Elran Haber - CEO, Biomica Yaron Eldad - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Nathan Weinstein - Aegis Capital Brett Reiss - Janney Montgomery Scott Brian Wright - ROTH Operator Ladies and gentlemen, thank you for standing by.

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q1 2022 Results - Earnings Call Transcript

Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates

Conference call and webcast: today, May 26, 2022, 9:00 am ET REHOVOT, Israel , May 26, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first quarter ended March 31, 2022.

Evogene Reports First Quarter 2022 Financial Results

REHOVOT, Israel , May 23, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at the ASCO 2022 Annual Meeting

REHOVOT, Israel , May 16, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference

Corteva Inc

Given wheat global shortages and high prices, Lavie foresees continued strong demand for its bio-inoculant result ™  and plans increased production for 2023 growing season REHOVOT, Israel , May 11, 2022 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

News for Evogene Stock (EVGN)